James Ulery, MD
Dermatology · Monroe, MINPI 1043313919
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by VYNE Pharmaceuticals Inc. at 43.4% of the total. Reporting peaked in 2020 at $9,900 and has fallen 80.2% since, to $1,965 in 2025. Among dermatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 699 payments — averaging $32.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- VYNE Pharmaceuticals Inc.$10K
- Johnson & Johnson$2K
- AbbVie$2K
- Almirall LLC$1K
- Novartis$862
- UCB, Inc.$780
- plus $6K from 30 others
Across 23 payments — averaging $2106.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$48K
What the payments were for
- Consulting fees$8004%
- Speaking & faculty fees$8,20036%
- Travel & lodging$9344%
- Food & beverage$11,90153%
- Education$6943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| VYNE Pharmaceuticals Inc. | 41 | $9,778 |
| Johnson & Johnson | 142 | $2,041 |
| AbbVie | 120 | $1,750 |
| Almirall LLC | 8 | $1,025 |
| Novartis | 46 | $862 |
| UCB, Inc. | 46 | $780 |
| E.r. Squibb & Sons, L.L.C. | 35 | $693 |
| Dermavant Sciences, Inc. | 15 | $664 |
| Sun Pharmaceutical Industries Inc. | 30 | $582 |
| Amgen | 51 | $580 |
| Pfizer | 28 | $510 |
| Galderma Laboratories, L.p. | 13 | $444 |
| Lilly USA, LLC | 28 | $405 |
| Sanofi | 12 | $356 |
| Journey Medical Corporation | 6 | $291 |
| Mayne Pharma Commercial LLC | 14 | $230 |
| Organon | 13 | $225 |
| Arcutis Biotherapeutics, Inc. | 8 | $221 |
| LEO Pharma Inc. | 7 | $206 |
| Verrica Pharmaceuticals Inc. | 2 | $185 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $161 |
| Dermira, Inc. | 5 | $96 |
| Regeneron Healthcare Solutions, Inc. | 4 | $75 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $67 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Incyte Corporation | 2 | $49 |
| Janssen Scientific Affairs, LLC | 1 | $36 |
| Bristol Myers Squibb | 2 | $31 |
| Botanix SB Inc | 1 | $25 |
| Strata Skin Sciences, Inc. | 2 | $24 |
| Aclaris Therapeutics, Inc. | 1 | $23 |
| Organogenesis Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Sebela Pharmaceuticals Inc. | 1 | $14 |
| Biofrontera Inc. | 1 | $12 |
| Prugen, Inc. Pharmaceuticals | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,529 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 12 | $159,317 |
| SotyktuDeucravacitinib | 13 | $80,629 |
| Pimecrolimus | 15 | $4,234 |
| Calcipotriene | 18 | $2,973 |
| Tacrolimus | 22 | $2,830 |
| Metronidazole | 51 | $2,235 |
| Ciclopirox | 59 | $1,899 |
| Clindamycin Phosphate | 49 | $1,805 |
| Dapsone | 12 | $957 |
| CiclopiroxCiclopirox Olamine | 57 | $922 |
| Fluocinolone Acetonide | 13 | $879 |
| Desonide | 22 | $563 |
| Econazole Nitrate | 32 | $484 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 12 | $479 |
| Hydroxychloroquine Sulfate | 11 | $425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,041 | $159,31712 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $693 | $80,62913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 dermatology providers in Michigan.
Other dermatology in Monroe
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
- Diana WestgateKalamazoo$252K
- Christofer BuattiAuburn Hills$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.